SPOTLIGHT: Medtronic's fortunes depend on new stent

Could Medtronic's new Endeavor stent make up for its multimillion-dollar losses from the recall of the Fidelis defibrillator lead? Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.